Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation

Journal of Clinical Laboratory Analysis

Volumn 22, Issue 1, 2008, Pages 6-13

  Hwang, Jawl Shan ^a   Wu, Tsu Lan ^a   Chou, S C ^a   Ho, C ^a   Chang, Pi Yueh ^a   Tsao, Kuo Chien ^a   Huang, Jeng Yi ^a   Sun, Chien Feng ^a   Wu, James T ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b ARUP LABORATORIES   (United States)

Author keywords

Cancer; Chronic inflammation; Inflammation markers; Macrovascular disease; Microvascular disease; Nephropathy; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CARCINOGENESIS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATIENT MONITORING; RISK ASSESSMENT;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 39449132731     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20207     Document Type: Article

References (34)

1. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004;4:237-246.
2. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes [Review]. Diabetes Care 2004;27:813-823.
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
4. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109 (Suppl 1):II2-II10.
5. Yao Q, Axelsson J, Stenvinkel P, Lindholm B. Chronic systemic inflammation in dialysis patients: an update on causes and consequences. ASAIO J 2004;50:lii-lvii.
6. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;12:5910-5918.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
8. Konig P, Goldstein D, Poehlmann M, Rife D, Ge B, Hewett J. Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis. Pediatr Pulmonol 2005;40:105-108.
9. Altman P. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J 2003;1:4-40.
10. Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005;32:1219-1223.
11. Beck JD, Pankow J, Tyroler HA, Offenbacher S. Dental infections and atherosclerosis. Am Heart J 1999;138:S528-S533.
12. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004;286:F442-F450.
13. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004;4:237-246.
14. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119.
15. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006;49:11-19.
16. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 2005;5:309-322.
17. Leinonen ES, Hiukka A, Hurt-Camejo E, et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med 2004;256:119-127.
18. Wu JT, Wu LL. Linking inflammation and atherogenesis: soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta 2006;366:74-80.
19. Wu JT, Wu LL. Association of soluble markers with various stages and major events of atherosclerosis [Review]. Ann Clin Lab Sci 2005;35:240-250.
20. Wu T-L, Chang P-Y, Li C-N, Tsao K-C, Sun C-F, Wu JT. Development of ELISA on microplate for C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta 2002;322:163-166.
21. Chang P-Y, Wu T-L, Tsao K-C, Li CC, Sun CF, Wu JT. Establishment of ELISAs on microplate for soluble VCAM-1 and ICAM. Ann Clin Lab Sci 2005;35:312-317.
22. Tsao K-C, Chang P-Y, Li CC, Wu T-L, Sun C-F, Wu JT. Development of an ELISA on microplate for circulating E-selectin: assay characterization, comparison with commercial kit and establishment of normal reference values. J Clin Lab Anal 2003;17:97-101.
23. Wu T-L, Sun YC, Hung CC, Chang PY, Wu JT. Development of an ELISA for serum IL-6 and determination of its serum level in healthy person and patients with type 2 diabetes. Clin Chem 2005;51:A7.
24. Wu TL, Chang PY, Li CC, Tsao KC, Sun CF, Wu JT. Microplate ELISA for urine microalbumin: reference values and results in patients with type 2 diabetes and cardiovascular disease. Ann Clin Lab Sci 2005:35:149-154.
25. Chan EC, Chang PY, Wu TL, Wu JT. Enzymatic assay of homocysteine on microtiter plates or a TECAN analyzer using crude lysate containing recombinant methionine μ-lyase. Ann Clin Lab Sci 2005;35:155-160.
26. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005;25:36-44.
27. Gori AM, Corsi AM, Fedi S, et al. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 2005;82:335-341.
28. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-1822.
29. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003;108:250-252.
30. Hayden M, Tyagi S. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
31. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42.
32. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
33. Kitsis RN, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 2006;355:513-515.
34. Sironi L, Gianazza E, Gelosa P, et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005;25:598-603.